Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Environmental Health Research|July 13, 2011
Microbial contamination of musical wind instrumentsBonnie Marshall, Stuart Levy
Nature Medicine|December 4, 2004
Antibacterial resistance worldwide: causes, challenges and responsesStuart B Levy, Bonnie Marshall
Antimicrobial Agents and Chemotherapy|July 27, 2004
Relationship between triclosan and susceptibilities of bacteria isolated from hands in the communityAllison E Aiello, Bonnie Marshall, Stuart B Levy, et al.
Emerging Infectious Diseases|December 2, 2005
Antibacterial cleaning products and drug resistanceAllison E Aiello, Bonnie Marshall, Stuart B Levy, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2014
Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infectionsRichard J Wallace, Gary Dukart, Barbara A Brown-Elliott, et al.
Journal of Pediatric Ophthalmology and Strabismus|November 15, 2011
Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throatSteven J Lichtenstein, Liberation De Leon, Warren Heller, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 12, 2008
A sensitive human bone assay for quantitation of tigecycline using LC/MS/MSAllena J Ji, James P Saunders, Peter Amorusi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancerManuel Hidalgo, Jan C Buckner, Charles Erlichman, et al.
Cancer Research|October 3, 2003
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinomaNatalie C Twine, Jennifer A Stover, Bonnie Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaMichael B Atkins, Manuel Hidalgo, Walter M Stadler, et al.
Pageof 2